| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 26.68 Billion | USD 56.05 Billion | 8.6% | 2023 |
List of Figures
1. Market research process
2. Market research methodology
3. Global Lung cancer therapeutics market revenue, 2016–2025 (USD Billion)
4. Porter’s Five Forces Analysis
5. Lung cancer therapeutics market attractiveness analysis, by Cancer type
6. Lung cancer therapeutics market attractiveness analysis, by Treatment
7. Lung cancer therapeutics market attractiveness analysis, by Drug Class
8. Lung cancer therapeutics market attractiveness analysis, by End-User
9. Lung cancer therapeutics market attractiveness analysis, by Distribution Channel
10. Lung cancer therapeutics market attractiveness analysis, by Region
11. Company market share analysis, 2018
12. Global Lung cancer therapeutics market share by Cancer type, 2018 and 2025
13. Global Lung cancer therapeutics market revenue for Non-Small Cell Lung Cancer, 2016–2025 (USD Billion)
14. Global Lung cancer therapeutics market revenue for Small Cell Lung Cancer, 2016–2025 (USD Billion)
15. Global Lung cancer therapeutics market share by Treatment, 2018 and 2025
16. Global Lung cancer therapeutics market revenue for Immunotherapy, 2016–2025 (USD Billion)
17. Global Lung cancer therapeutics market revenue for Chemotherapy, 2016–2025 (USD Billion)
18. Global Lung cancer therapeutics market revenue for Targeted Therapy, 2016–2025 (USD Billion)
19. Global Lung cancer therapeutics market revenue for Radiation Therapy, 2016–2025 (USD Billion)
20. Global Lung cancer therapeutics market revenue for Others, 2016–2025 (USD Billion)
21. Global Lung cancer therapeutics market share by Drug Class, 2018 and 2025
22. Global Lung cancer therapeutics market revenue for Antimetabolites, 2016–2025 (USD Billion)
23. Global Lung cancer therapeutics market revenue for Alkylating Agents2016–2025 (USD Billion)
24. Global Lung cancer therapeutics market revenue for Mitotic Inhibitors, 2016–2025 (USD Billion)
25. Global Lung cancer therapeutics market revenue for EGFR Inhibitors, 2016–2025 (USD Billion)
26. Global Lung cancer therapeutics market revenue for Multikinase Inhibitors, 2016–2025 (USD Billion)
27. Global Lung cancer therapeutics market revenue for Others, 2016–2025 (USD Billion)
28. Global Lung cancer therapeutics market share by End-User, 2018 and 2025
29. Global Lung cancer therapeutics market revenue for Hospitals, 2016–2025 (USD Billion)
30. Global Lung cancer therapeutics market revenue for Homecare, 2016–2025 (USD Billion)
31. Global Lung cancer therapeutics market revenue for Specialty Clinics, 2016–2025 (USD Billion)
32. Global Lung cancer therapeutics market revenue for Others, 2016–2025 (USD Billion)
33. Global Lung cancer therapeutics market share by Distribution Channel, 2018 and 2025
34. Global Lung cancer therapeutics market revenue for Retail Pharmacy, 2016–2025 (USD Billion)
35. Global Lung cancer therapeutics market revenue for Hospital Pharmacy, 2016–2025 (USD Billion)
36. Global Lung cancer therapeutics market revenue for Internet, 2016–2025 (USD Billion)
37. Global Lung cancer therapeutics market revenue for Others, 2016–2025 (USD Billion)
38. Global Lung cancer therapeutics market share by Region, 2018 and 2025
39. North America Lung cancer therapeutics market revenue, 2016–2025 (USD Billion)
40. Europe Lung cancer therapeutics market revenue, 2016–2025 (USD Billion)
41. Asia Pacific Lung cancer therapeutics market revenue, 2016–2025 (USD Billion)
42. Latin America Lung cancer therapeutics market revenue, 2016–2025 (USD Billion)
43. The Middle East and Africa Lung cancer therapeutics market revenue, 2016–2025 (USD Billion)
List of Tables
1. Lung Cancer Therapeutics Market: Market snapshot
2. Drivers of the Global Lung Cancer Therapeutics Market: Impact analysis
3. Restraints of the Global Lung Cancer Therapeutics Market: Impact analysis
4. North America Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
5. North America Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
6. North America Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
7. North America Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
8. North America Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
9. The U.S. Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
10. The U.S. Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
11. The U.S. Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
12. The U.S. Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
13. The U.S. Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
14. Rest of North America Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
15. Rest of North America Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
16. Rest of North America Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
17. Rest of North America Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
18. Rest of North America Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
19. Europe Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
20. Europe Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
21. Europe Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
22. Europe Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
23. Europe Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
24. Germany Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
25. Germany Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
26. Germany Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
27. Germany Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
28. Germany Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
29. U.K. Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
30. U.K. Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
31. U.K. Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
32. U.K. Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
33. U.K. Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
34. France Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
35. France Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
36. France Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
37. France Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
38. France Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
39. Rest of Europe Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
40. Rest of Europe Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
41. Rest of Europe Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
42. Rest of Europe Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
43. Rest of Europe Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
44. Asia Pacific Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
45. Asia Pacific Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
46. Asia Pacific Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
47. Asia Pacific Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
48. Asia Pacific Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
49. China Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
50. China Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
51. China Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
52. China Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
53. China Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
54. Japan Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
55. Japan Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
56. Japan Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
57. Japan Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
58. Japan Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
59. India Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
60. India Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
61. India Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
62. India Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
63. India Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
64. Rest of Asia Pacific Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
65. Rest of Asia Pacific Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
66. Rest of Asia Pacific Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
67. Rest of Asia Pacific Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
68. Rest of Asia Pacific Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
69. Latin America Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
70. Latin America Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
71. Latin America Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
72. Latin America Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
73. Latin America Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
74. Brazil Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
75. Brazil Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
76. Brazil Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
77. Brazil Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
78. Brazil Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
79. Rest of Latin America Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
80. Rest of Latin America Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
81. Rest of Latin America Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
82. Rest of Latin America Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
83. Rest of Latin America Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
84. The Middle East and Africa Lung cancer therapeutics market revenue, by Cancer type, 2016–2025 (USD Billion)
85. The Middle East and Africa Lung cancer therapeutics market revenue, by Treatment, 2016–2025 (USD Billion)
86. The Middle East and Africa Lung cancer therapeutics market revenue, by Drug Class, 2016–2025 (USD Billion)
87. The Middle East and Africa Lung cancer therapeutics market revenue, by End-User, 2016–2025 (USD Billion)
88. The Middle East and Africa Lung cancer therapeutics market revenue, by Distribution Channel, 2016–2025 (USD Billion)
FrequentlyAsked Questions
Lung cancer therapeutics are treatments used to manage lung cancer. They include chemotherapy, targeted therapy, and immunotherapy.
The global lung cancer therapeutics market is expected to be driven by the rising lung cancer incidence, targeted therapy adoption, and advances in oncology drug development.
According to study, the global lung cancer therapeutics market size was worth around USD 26.68 Billion in 2023 and is predicted to grow to around USD 56.05 Billion By 2032.
The global lung cancer therapeutics market is expected to grow at a Compound Annual Growth Rate (CAGR) of around CAGR 8.6% during the forecast period from 2024-2032.
The global lung cancer therapeutics industry is projected to be challenged by Key challenges include long clinical trials, high R&D costs, and regulatory approvals. Drug resistance and reimbursement pressure affect commercialization.
The Opportunities include targeted therapies, immuno-oncology combinations, and early-detection-linked treatments. Biomarker-driven care and expanded indications fuel growth will offer significant growth opportunities in the lung cancer therapeutics market.
Targeted therapies and immuno-oncology drugs; biomarker-driven treatment selection; combination therapy innovations are the emerging trends and innovations impacting the lung cancer therapeutics market.
The global lung cancer therapeutics market is expected to be led by North America during the forecast period.
Some of the prominent players operating in the global lung cancer therapeutics market are; Hoffmann-La Roche, Eli Lilly and Company, Sanofi-Aventis, Pfizer, Celgene Corporation, GlaxoSmithKline, Boehringer Ingelheim, Agennix, AstraZeneca, and Merck & Co and others.
The report explores crucial aspects of the lung cancer therapeutics market, including a detailed discussion of existing growth factors and restraints, while also browsing future growth opportunities and challenges that impact the market.
HappyClients